Oeda Satoshi, Mizuta Toshihiko, Isoda Hiroshi, Kuwashiro Takuya, Iwane Shinji, Takahashi Hirokazu, Kawaguchi Yasunori, Eguchi Yuichiro, Ozaki Iwata, Tanaka Keitaro, Fujimoto Kazuma
Hepatogastroenterology. 2013 Sep;60(126):1399-404. doi: 10.5754/hge121270.
BACKGROUND/AIMS: The aims of this study were to compare long-term prognosis of patients with hepatocellular carcinoma (HCC) treated with radiofrequency ablation (RFA) and percutaneous ethanol injection (PEI).
Two hundred and thirteen patients with HCC were initially treated with PEI or RFA at Saga University Hospital between 1990 and 2004. The present study included 190 patients: 98 treated with PEI from 1990 to 1999, and 92 with RFA from 2000 to 2004. The association of treatment method with survival prognosis was evaluated by multivariate analysis.
There were no significant differences in gender, etiology, and tumor stage between the two groups. Five-year survival rate in the PEI group was 40% and 51% in the RFA group. According to tumor stage, there were no differences in 5-year survival rate between the two groups for tumor stage I and III. For stage II patients, RFA had better survival than PEI (48% vs. 28%, p = 0.03). Multivariate analysis indicated that RFA was more effective for long-term survival than PEI in patients with tumor stage II (p = 0.04).
Compared to PEI, RFA improved survival in patients with stage II HCC, indicating a therapeutic advantage of RFA.
背景/目的：本研究旨在比较接受射频消融（RFA）和经皮乙醇注射（PEI）治疗的肝细胞癌（HCC）患者的长期预后。
1990年至2004年期间，213例HCC患者最初在佐贺大学医院接受PEI或RFA治疗。本研究纳入190例患者：1990年至1999年期间98例接受PEI治疗，2000年至2004年期间92例接受RFA治疗。通过多因素分析评估治疗方法与生存预后的相关性。
两组在性别、病因和肿瘤分期方面无显著差异。PEI组的5年生存率为40%，RFA组为51%。根据肿瘤分期，I期和III期肿瘤患者两组的5年生存率无差异。对于II期患者，RFA的生存率优于PEI（48%对28%，p = 0.03）。多因素分析表明，对于II期肿瘤患者，RFA在长期生存方面比PEI更有效（p = 0.04）。
与PEI相比，RFA提高了II期HCC患者的生存率，表明RFA具有治疗优势。
